SNCA and Parkinson disease: These compounds are capable of reducing the beta amyloid (Aβ) aggregation by increasing monoamine secretion in AD and PD (8), preventing abnormal accumulation of Aβ and α-synuclein in AD and PD (9), acting as an antioxidant against AD (3, 5–11), improving blood flow to the cerebral, and improving cognition and performance in AD, PD, HD, and multiple sclerosis (11).